GUT METATRANSCRIPTOMICS AND METABOLOMICS REVEAL ASSOCIATION OF CYSTEINE AND PURINE METABOLISMS WITH METABOLIC ASSOCIATED FATTY LIVER DISEASE (MAFLD)

MASCARDI MF; MAZZINI F; RUDA V; PANDIT S; MANSUR L; WANG Y; GOUNARIDES J; COOK F; MARCIANO S; HADDAD L; TAMAROFF AJ ; CASCIATO P; NARVAEZ A; ANDERS M; OROZCO F; GUTT S; GADANO A; MENDEZ GARCIA C; MARRO, MARTIN; PENAS STEINHARDT A; TRINKS J

Congreso; The Liver Meeting 2021; 2021

American Association for the Study of Liver Diseases

Background: The gut microbiome represents a niche for biomarkers discovery to risk-stratify MAFLD patients. However, each population may have unique microbiome signatures and studies are needed in Latin America where MAFLD prevalence and severity are high. Therefore, theaim of this study was to identify gut metatranscriptome and metabolome signatures associated with MAFLD and steatohepatitis (SH) in Argentina. Methods: Stool samples, diet, demographic and clinical data were obtained from 33 biopsy-proven patients (12 simple steatosis -SS- and 21 SH) and 19 healthy volunteers (HV). PNPLA3 rs738409 SNP was genotyped. HPLC, flow injection analysis with MS/MS in tandem and MetaboAnalyst-v4.0 were used for metabolomics. RNA-seq was performed in NovaSeq6000®. bioBakery-v1.8 and Maaslin2-v1.2.0 were used for data analysis. Results: BMI was higher in MAFLD patients, particularly in SH (q=4.49e-06). After adjusting for BMI, 89 and 53 gene family clusters were differentially expressed between HV and MAFLD and between SS and SH, respectively (q